A key congressional panel has voted to block the federal rescheduling of marijuana—even though the Trump administration announced last week that it is moving ahead with enacting the reform.
The House Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies on Thursday approved a funding bill containing a provision that, if enacted, would prevent federal officials from taking further steps to carry out cannabis rescheduling.
“SEC. 591. None of the funds appropriated under this Act or otherwise made available by this Act may be used to reschedule marijuana (as such term is defined in section 102 of the Controlled Substances Act (21 U.S.C. 802)) or to remove marijuana from the schedules established under section 202 of the Controlled Substances Act (21 U.S.C. 812).”
The committee has advanced similar language in the past years as the federal government has weighed marijuana rescheduling, but those provisions were never passed into law.
The Department of Justice announced last week that marijuana products regulated by a state medical cannabis license immediately moved to Schedule III, as did any marijuana products that are approved by the Food and Drug Administration (FDA). An administrative hearing scheduled for this summer will consider broader cannabis rescheduling.
Because the
Read full article on Marijuana Moment
